American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 262-269 , August 2009

Association of Level of Kidney Function and Platelet Aggregation in Acute Myocardial Infarction

  • Fredrik Karlsson, MD

      Affiliations

    • Department of Internal Medicine, Section of Cardiology, Östersund Hospital, Östersund, Sweden
    • Department of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden
    • Corresponding Author InformationAddress correspondence to Fredrik Karlsson, MD, Medicinkliniken, Östersunds sjukhus, 83131 Östersund, Sweden
    • ,
  • Angelo Modica, MD

      Affiliations

    • Department of Internal Medicine, Section of Cardiology, Östersund Hospital, Östersund, Sweden
    • Department of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden
    • ,
  • Thomas Mooe, MD, PhD

      Affiliations

    • Department of Internal Medicine, Section of Cardiology, Östersund Hospital, Östersund, Sweden
    • Department of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden

Received 10 October 2008 ,Accepted 3 April 2009.

References 

  1. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356:147–152
  2. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002;62:1402–1407
  3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  4. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47–55
  5. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169
  6. Santopinto JJ, Fox KA, Goldberg RJ, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: Findings from the Global Registry of Acute Coronary Events (GRACE). Heart. 2003;89:1003–1008
  7. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–1295
  8. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342–2348
  9. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100
  10. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost. 2006;4:2547–2552
  11. Karlsson F, Modica A, Mooe T. Dynamics of platelet activation in diabetic and non-diabetic subjects during the course of an acute myocardial infarction. Thromb Res. 2007;121:269–273
  12. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined—A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  13. Grubb A, Nyman U, Bjork J, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the Modification of Diet in Renal Disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem. 2005;51:1420–1431
  14. Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem. 1994;40:1921–1926
  15. Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem. 1994;218:284–294
  16. Eto K, Takeshita S, Ochiai M, Ozaki Y, Sato T, Isshiki T. Platelet aggregation in acute coronary syndromes: Use of a new aggregometer with laser light scattering to assess platelet aggregability. Cardiovasc Res. 1998;40:223–229
  17. Miyamoto S, Sakamoto T, Soejima H, et al. Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction. Am Heart J. 2003;146:465–471
  18. Fusegawa Y, Goto S, Handa S, Kawada T, Ando Y. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb Res. 1999;93:271–278
  19. Kajiwara I, Ogawa H, Soejima H, et al. The prognostic value of small-sized platelet aggregates in unstable angina: Detection by a novel laser-light scattering method. Thromb Res. 2001;101:109–118
  20. McCullough PA. Why is chronic kidney disease the “spoiler” for cardiovascular outcomes?. J Am Coll Cardiol. 2003;41:725–728
  21. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140:9–17
  22. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92
  23. Landray MJ, Wheeler DC, Lip GY, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: The Chronic Renal Impairment in Birmingham (CRIB) Study. Am J Kidney Dis. 2004;43:244–253
  24. Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost. 2007;5:507–511
  25. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA. 1998;279:1477–1482
  26. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004;30:579–589
  27. Gurm HS, Lincoff AM, Lee D, et al. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: Lessons from the GUSTO V trial. J Am Coll Cardiol. 2004;43:542–548
  28. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015
  29. Fernandez JS, Sadaniantz BT, Sadaniantz A. Review of antithrombotic agents used for acute coronary syndromes in renal patients. Am J Kidney Dis. 2003;42:446–455
  30. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–256
  31. Harding SA, Din JN, Sarma J, Josephs DH, Fox KA, Newby DE. Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. Heart. 2006;92:1635–1638
  32. Satoh K, Ozaki Y, Qi R, et al. Factors that affect the size of platelet aggregates in epinephrine-induced activation: A study using the particle counting method based upon light scattering. Thromb Res. 1996;81:515–523
  33. Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: Involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost. 2006;4:1271–1278

 Originally published online as doi:10.1053/j.ajkd.2009.04.023 on June 29, 2009.

PII: S0272-6386(09)00750-1

doi: 10.1053/j.ajkd.2009.04.023

American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 262-269 , August 2009

Article Tools

* Image Usage & Resolution